Vertex Pharmaceuticals Incorporated (VRTX) P/E Ratio History
Historical price-to-earnings valuation from 1993 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a price-to-earnings ratio of 32.4x, with a stock price of $496.83 and trailing twelve-month earnings per share of $14.27.
The current P/E is 16% above its 5-year average of 27.9x. Over the past five years, VRTX's P/E has ranged from a low of 20.5x to a high of 48.5x, placing the current valuation at the 85th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, VRTX trades at a 37% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 3.91 (P/E divided by 837% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, VRTX commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VRTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Rare Disease Biopharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
VRTXVertex Pharmaceuticals Incorporated | $126B | 32.4 | 3.91 | +837% |
BMRNBioMarin Pharmaceutical Inc. | $12B | 34.3 | - | +1186%Best |
PTCTPTC Therapeutics, Inc. | $5B | 8.8 | - | +264% |
CORTCorcept Therapeutics Incorporated | $4B | 43.5 | - | -33% |
CPRXCatalyst Pharmaceuticals, Inc. | $3B | 13.7 | 0.73Best | +28% |
BCRXBioCryst Pharmaceuticals, Inc. | $2B | 7.2Lowest | - | +381% |
HRMYHarmony Biosciences Holdings, Inc. | $2B | 10.5 | - | +8% |
PLXProtalix BioTherapeutics, Inc. | $218M | 78.7 | - | -63% |
SLNOSoleno Therapeutics, Inc. | $145,692 | 100.2 | - | +109% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $391.64 | $14.18 | 27.6x | -75% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $445.20 | $13.99 | 31.8x | -71% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $418.01 | $15.41 | 27.1x | -75% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $406.89 | $13.89 | 29.3x | -73% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $347.74 | $13.33 | 26.1x | -76% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $351.91 | $12.95 | 27.2x | -75% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $315.07 | $12.56 | 25.1x | -77% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $288.78 | $12.83 | 22.5x | -79% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $289.54 | $12.68 | 22.8x | -79% |
| FY2022 Q2 | $281.79 | $12.37 | 22.8x | -79% | |
| FY2022 Q1 | $260.97 | $9.50 | 27.5x | -75% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $219.60 | $9.03 | 24.3x | -78% |
Average P/E for displayed period: 109.6x
See VRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VRTX vs AGIO
See how VRTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is VRTX stock overvalued or undervalued?
VRTX trades at 32.4x P/E, near its 5-year average of 27.9x. The 85th percentile ranking places valuation within normal historical bounds.
How does VRTX's valuation compare to peers?
Vertex Pharmaceuticals Incorporated P/E of 32.4x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is VRTX's PEG ratio?
VRTX PEG ratio is 3.91. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1993-2025.